RE: CP broke the law by NOT notifying investors of the business changes and sudden suspension?8 Mar 2023 21:02
Sent by EMAIL
Tuesday, 8 December 2020
Mr Nikhil Rathi, Chief Executive FCA
Misrepresentation Act 1967 Dear Mr Rathi,
nikhil.rathi@fca.org.uk
CC: consumer.queries@fca.org.uk
Complaint
Cameron John Parry, CEO of TallyMoney,
formerly Lionsgold (LION), formerly Kolar Gold.
I should like to bring to your attention the aforementioned Cameron John Parry the son of the late Mr
Kevin PARRY of the infamous ASTOP Biohealth, only now he is perpetuating similar with duping
investors In the England.
Mr Parry seemingly unwarrantedly delisted the company(LION) (from the ALTERNATIVE INVESTMENT
MARKET (AIM) and since 11th May 2018, he has made numerous statements to re-list the company.
Such as: ‘The Directors now expect that the readmission process will be completed in the fourth
quarter of this calendar year instead of late Q3, 2018’1
Friday the 19th Oct 2018
the then company chair, practising solicitor MICHAEL CORCORAN.SRA ID:
362065; SRA Regulated, quoted a relist in Q1 2019 when there was never any hope of doing so. Was this
premeditated deception? Corcoran: ‘The Board remains committed to restoring the Company's shares
to being quoted on AIM and is targeting a date in Q1 2019 for readmission.
Other purposeful deceptive statements include those found on the financial program PROACTIVE
INVESTORS. '2018 is going to be huge for us', says Lionsgold CEO Cameron Parry3
,
’2
LION was suspended from trading, due to a "fundamental change of business" – Cameron Parry as CEO
would have been aware of this listing regulation and so the company suspension, to reiterate previous,
can be seen as a deliberate action on Parry’s behalf.
'Lionsgold’s ordinary shares will remain suspended until the Company fully complies with Rule 14. This
process is expected to take three to four months to complete.' - Lionsgold issued this statement and I
think it is beyond doubt that Cameron Parry has made no effort to comply with rule 14.
Rule 14. is there to protect shareholder investment and NOT for CEO's to circumvent listing regulations
contrary to shareholders best interests.
I would like to know how and why, given Parry’s background with ASTOP BIOHEALTH
4
, was he allow to
trade in the UK? One can plainly see the similarities between Parry’s apparent deception of
shareholders at Tally in Britain and those investors in ASTOP in Australia5.
Parry has made varying impossible statements, including outrageous statements like "a seat at the
world banking table"& “And finally, we wish to reassure all shareholders of our complete commitment
to see the Company make application to recommencing trading of its shares on AIM in Q1 2019”6
Mr Parry keeps dragging out the company’s relisting thereby depriving shareholders of the ability to
trade their shares, whilst Mr Parry rakes off 200,000 pounds sterling per annum for very little, whilst
focusing on his other more lucrative businesses7
I trust that the authorities will investiga
Sign In
Follow the stocks
